GlassScriptPhysician profile
William A Rios
NPI 1164443644
$4,891.90
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $346 · 2021: $975 · 2022: $968 · 2023: $1,413 · 2024: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $685.72 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $449.68 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.73 | 2019-2024 | Jardiance |
| Amgen INC. | $347.33 | 2019-2023 | Prolia, Evenity |
| Abbvie INC. | $342.02 | 2019-2024 | Vraylar |
| Esperion Therapeutics, INC. | $322.77 | 2020-2023 | Nexletol |
| Pfizer INC. | $261.42 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.23 | 2021-2023 | |
| Boston Scientific Corporation | $182.12 | 2024 | Watchman Flx |
| Amarin Pharma, INC. | $177.30 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $144.99 | 2022 | |
| Ucb, INC. | $122.56 | 2023 | |
| Merck Sharp & Dohme LLC | $122.10 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $119.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $117.39 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.